Observational biomarker study related to the resistance mechanism of 3rd generation EGFR-TKI (osimertinib)(LOGIK1607)
Not Applicable
- Conditions
- EGFR mutation positive and T790M positive non-small cell lung cancer
- Registration Number
- JPRN-UMIN000025290
- Lead Sponsor
- Clinical Research Support Center Kyushu
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who receive osimertinib concurrently with other cytotoxic agents, molecular targeting agents or immune-checkpoint inhibitors are excluded. Patients whose tumor specimens cannot meet the eligibility criteria or the "paired" specimens (pre and post osimertinib treatment) cannot be submitted are also excluded.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method